Molbio Diagnostics IPO Day 1: Subscription Status, Timeline & Key Issue Details

The ₹939.70 crore Molbio Diagnostics initial public offering (IPO) opened for public subscription today, August 10, 2026, with a price band of ₹768 to ₹807 per share. As of 10:30 AM on the first day of bidding, the issue had been subscribed 0.07 times.

The IPO will remain open for subscription until August 12, 2026. The basis of allotment is expected to be finalised on August 13, 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on August 17, 2026.

Molbio Diagnostics IPO - Issue Details

• Issue Type: Book Built Issue (Fresh Issue + OFS)
• Total Issue Size: Up to ₹939.70 crore
• Fresh Issue: Up to ₹200.00 crore
• Offer for Sale (OFS): Up to 739.70 crore 
• Face Value: ₹1 per equity share
• Price Band: To be announced
• Lot Size: To be announced
• Minimum Investment Amount (Retail Investor): ₹14,526 (18 shares at the upper price)
• Listing: BSE, NSE
• Book Running Lead Managers: Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited
• Registrar: KFin Technologies Limited

Molbio Diagnostics IPO Timeline (Tentative)

The expected IPO schedule is as follows:

Note: The allotment and listing dates are tentative and may be revised.

Utilisation of IPO Proceeds

The company intends to utilise the net proceeds from the fresh issue towards:

• Funding capital expenditure for setting up infrastructure for a research and development facility and Centre of Excellence to be operated by the wholly owned subsidiary, Bigtec, along with office space for the company, its subsidiaries and associates.
• Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
• General corporate purposes

Molbio Diagnostics IPO Day 1 Subscription Status

[August 10, 2026, 10:30 A.M.]

About Molbio Diagnostics Limited

Molbio Diagnostics Limited, founded in 2000, specialises in point-of-care (POC) diagnostic solutions, with a focus on making molecular testing faster and more affordable for infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable, battery-powered PCR system developed for settings with limited resources and can provide test results in about an hour. As of March 31, 2026, the company’s portfolio covered 30 diseases through 43 assays, including tests for tuberculosis (TB), COVID-19, HIV, hepatitis B and C, and HPV.

Beyond molecular diagnostics, Molbio offers solutions across areas such as radiology, digital pathology and breast health screening through its subsidiaries and strategic partners. The Truenat technology has received patent protection in more than 100 countries. Its tuberculosis test is also among the rapid molecular diagnostic tests recommended by the World Health Organization (WHO) for the initial detection of TB and rifampicin resistance.

Key Financial Highlights 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.  

To read the RA disclaimer, please click here